Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Beam Therapeutics Dividend Announcement
• Beam Therapeutics announced a quarterly dividend of $0.23 per ordinary share which will be made payable on 2014-03-03. Ex dividend date: 2014-02-04
• Beam Therapeutics's trailing twelve-month (TTM) dividend yield is -%
Beam Therapeutics Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2014-02-04 | $0.23 | quarterly | 2014-03-03 |
2013-11-04 | $0.23 | quarterly | 2013-12-02 |
2013-08-12 | $0.23 | quarterly | 2013-09-03 |
2013-05-06 | $0.23 | quarterly | 2013-06-03 |
2013-02-04 | $0.23 | quarterly | 2013-03-01 |
2012-11-05 | $0.21 | quarterly | 2012-12-03 |
2012-08-06 | $0.21 | quarterly | 2012-09-04 |
2012-05-07 | $0.21 | quarterly | 2012-06-01 |
2012-02-06 | $0.21 | quarterly | 2012-03-01 |
2011-11-07 | $0.19 | quarterly | 2011-12-01 |
Beam Therapeutics Dividend per year
Beam Therapeutics Dividend growth
Beam Therapeutics Dividend Yield
Beam Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Beam Therapeutics stock? Use our calculator to estimate your expected dividend yield:
Beam Therapeutics Financial Ratios
Beam Therapeutics Dividend FAQ
Other factors to consider when evaluating Beam Therapeutics as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Beam Therapeutics stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Beam Therapeutics's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Beam Therapeutics publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Beam Therapeutics distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Beam Therapeutics are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Beam Therapeutics sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Beam Therapeutics distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Beam Therapeutics declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Beam Therapeutics's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Beam Therapeutics's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.